30 closest matches · ranked by relevance
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Hepatorenal Syndrome
Primary: Percentage of Participants With Verified HRS Reversal — 29.1; 15.8 percentage of participants
Hepatorenal Syndrome
Primary: Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide — 36.0; 11.9; 15.7; 10.5 hours
Hepatorenal Syndrome
Primary: Percentage of Participants With Confirmed Hepatorenal Syndrome (HRS) Reversal — 19.6; 13.1 percentage of participants
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
Cardiorenal Syndrome
Primary: Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values — 8; 5 Participants
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virologic Response at 24 Weeks Following Treatment Completion — 55.6 Percentage of participants
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Septic Shock · Acute Kidney Injury
Primary: Change in Plasma Renin Levels — -15; 69; -6; 26 pg/mL
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment — 39.5; 34.9 percentage of participants — p=0.6746
Compensated Cirrhosis and Portal Hypertension
Primary: Change From Baseline of the Blood Flow for the Total Renal Arteries (Study Part A (Serelaxin Treatment Group Only)) — 0.438 L/min
HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 40.0; 60.0; 100.0 percentage of participants
Hepatitis Viruses
Primary: Number of Participants With Sustained Virologic Response (SVR12) — 46 Participants
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
Acute Decompensated Heart Failure
Primary: Renal Function by Serum Creatinine — 1.3; 1.3; 1.3; 1.4 mg/dL
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
Cardiorenal Syndrome (CRS)
Primary: Change in Glomerular Filtration Rate — -5; 1.00 ml/min/1.73 m2 — p=0.26
Hepatocellular Carcinoma
Primary: Progression — 11 participants
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Chronic Hepatitis C · Hepatitis C Virus · Compensated Cirrhosis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment — 94.1 percentage of participants
Total Fluid Volume Increased
Primary: Concentration of NGAL in Urine on 5 Time Point — 5.6; 4.9; 5.2; 5.1 ng/ml
Postural Orthostatic Tachycardia Syndrome (POTS)
Primary: Mean Arterial Blood Pressure Change — 14; 10 mmHg
Liver Disease
Primary: Results of HepQuant SHUNT Test: Elimination Rate (IV Phase 1 Only; Min-1) — 0.104; 0.092; 0.099 min-1
Acute Kidney Injury
Primary: Mortality — 96; 34 Participants — p=<0.0001
Chronic Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98.1 percentage of participants
Pleural Effusion
Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
Acute Renal Failure
Primary: Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF) — 56; 49…